{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:08:05Z","timestamp":1783987685675,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T00:00:00Z","timestamp":1465344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12894-016-0148-4","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T09:27:12Z","timestamp":1465378032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials"],"prefix":"10.1186","volume":"16","author":[{"given":"Masahiko","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomihiro","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutake","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"issue":"4","key":"148_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"C Fitzmaurice","year":"2015","unstructured":"Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505\u201327.","journal-title":"JAMA Oncol"},{"issue":"6","key":"148_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1084\/jem.70.6.543","volume":"70","author":"C Huggins","year":"1939","unstructured":"Huggins C, Masina MH, Eichelberger L, Wharton JD. Quantitative studies of prostatic secretion : I. Characteristics of the normal secretion; the influence of thyroid, suprarenal, and tstis extirpation and androgen substitution on the prostatic output. J Exp Med. 1939;70(6):543\u201356.","journal-title":"J Exp Med"},{"issue":"5\u20136","key":"148_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","volume":"50","author":"SE Barrie","year":"1994","unstructured":"Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50(5\u20136):267\u201373.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"21","key":"148_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"2","key":"148_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"148_CR6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/jjco\/hyu148","volume":"44","author":"T Satoh","year":"2014","unstructured":"Satoh T, Uemura H, Tanabe K, Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono S, Akaza H. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol. 2014;44(12):1206\u201315.","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"148_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/jjco\/hyu149","volume":"44","author":"N Matsubara","year":"2014","unstructured":"Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol. 2014;44(12):1216\u201326.","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"148_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148\u201359.","journal-title":"J Clin Oncol"},{"issue":"3","key":"148_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","volume":"61","author":"AJ Armstrong","year":"2012","unstructured":"Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(3):549\u201359.","journal-title":"Eur Urol"},{"issue":"25","key":"148_CR10","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","volume":"23","author":"L Collette","year":"2005","unstructured":"Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. 2005;23(25):6139\u201348.","journal-title":"J Clin Oncol"},{"issue":"31","key":"148_CR11","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","volume":"31","author":"S Halabi","year":"2013","unstructured":"Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013;31(31):3944\u201350.","journal-title":"J Clin Oncol"},{"issue":"6","key":"148_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2217\/fon.14.24","volume":"10","author":"O Caffo","year":"2014","unstructured":"Caffo O, Veccia A, Maines F, Bonetta A, Spizzo G, Galligioni E. Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. Future Oncol. 2014;10(6):985\u201393.","journal-title":"Future Oncol"},{"issue":"14","key":"148_CR13","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","volume":"21","author":"XS Xu","year":"2015","unstructured":"Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, et al. Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients. Clin Cancer Res. 2015;21(14):3170\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2_suppl","key":"148_CR14","first-page":"249","volume":"34","author":"JR Guccione","year":"2016","unstructured":"Guccione JR, Ledet EM, Stolten MD, Steinberger AE, Chow LD, Cotogno P, Lewis BE, Sartor AO. Early assessment of PSA response in CRPC patients treated with enzalutamide (Enza) or abiraterone (Abi). ASCO Meeting Abstracts. 2016;34(2_suppl):249.","journal-title":"ASCO Meeting Abstracts"},{"issue":"2_suppl","key":"148_CR15","first-page":"231","volume":"34","author":"V Conteduca","year":"2016","unstructured":"Conteduca V, Crabb SJ, Scarpi E, Hanna C, Maines F, Joyce H, Fabbri P, Derosa L, Massari F, Lolli C, et al. Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. ASCO Meeting Abstracts. 2016;34(2_suppl):231.","journal-title":"ASCO Meeting Abstracts"},{"issue":"11","key":"148_CR16","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"148_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-12-2910","volume":"19","author":"J Hoffman-Censits","year":"2013","unstructured":"Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(6):1335\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"148_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/01.cad.0000231468.69535.97","volume":"17","author":"PJ Olbert","year":"2006","unstructured":"Olbert PJ, Hegele A, Kraeuter P, Heidenreich A, Hofmann R, Schrader AJ. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs. 2006;17(8):993\u20136.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"148_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clgc.2014.06.010","volume":"13","author":"SL Burgio","year":"2015","unstructured":"Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, Fabbri P, Montanari M, Carretta E, Menna C, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39\u201343.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"148_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.12788\/jcso.0045","volume":"12","author":"SK Narmala","year":"2014","unstructured":"Narmala SK, Boulmay BC. PSA flare after initiation of abiraterone acetate. J Community Support Oncol. 2014;12(5):191\u20132.","journal-title":"J Community Support Oncol"},{"issue":"1","key":"148_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11255-007-9221-y","volume":"40","author":"T Nelius","year":"2008","unstructured":"Nelius T, Klatte T, de Riese W, Filleur S. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol. 2008;40(1):97\u2013104.","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"148_CR22","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.ejca.2014.03.015","volume":"50","author":"A Angelergues","year":"2014","unstructured":"Angelergues A, Maillet D, Flechon A, Ozguroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2014;50(9):1602\u20139.","journal-title":"Eur J Cancer"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-016-0148-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-016-0148-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-016-0148-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-016-0148-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:30:33Z","timestamp":1526639433000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-016-0148-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1186\/s12894-016-0148-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]},"article-number":"27"}}